MPR Weekly Dose 136 — Approvals in Multiple Myeloma, Axial Spondyloarthritis, and Hepatocellular Carcinoma; FDA Panel Vote; Oral Suspension of Tadalafil

<p><span style="font-weight: 400;">Approvals for relapsed or refractory multiple myeloma, non-radiographic axial spondyloarthritis, and unresectable hepatocellular carcinoma; advisory committee takes vote on potential treatment for anemia of chronic kidney disease; and an oral formulation of pulmonary arterial hypertension treatment.</span></p>